# Efficacy of the Combination of Trimipramine and Atezolizumab With Bevacizumab in Patients With Recurrent Glioblastoma: a Phase 2 Trial

> **NCT07263438** · PHASE2 · RECRUITING · sponsor: **Centre Hospitalier Universitaire Vaudois** · enrollment: 59 (estimated)

## Conditions studied

- Glioblastoma
- Recurrence Tumor

## Interventions

- **DRUG:** Trimipramine
- **BIOLOGICAL:** Cohort 1: Atezolizumab
- **BIOLOGICAL:** Bevacizumab
- **BIOLOGICAL:** Cohort 2: Atezolizumab
- **BIOLOGICAL:** Cohort 2: Bevacizumab

## Key facts

- **NCT ID:** NCT07263438
- **Lead sponsor:** Centre Hospitalier Universitaire Vaudois
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-11-03
- **Primary completion:** 2028-03-30
- **Final completion:** 2030-12-31
- **Target enrollment:** 59 (ESTIMATED)
- **Last updated:** 2026-02-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07263438

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07263438, "Efficacy of the Combination of Trimipramine and Atezolizumab With Bevacizumab in Patients With Recurrent Glioblastoma: a Phase 2 Trial". Retrieved via AI Analytics 2026-08-11 from https://api.ai-analytics.org/clinical/NCT07263438. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*